コンテンツへスキップ
Merck
  • Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.

Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.

Diagnostic microbiology and infectious disease (2017-12-03)
Katharina Neudorfer, Suzannah M Schmidt-Malan, Robin Patel
要旨

We tested the in vitro activity of dalbavancin, vancomycin and daptomycin against 83 enterococcal isolates in planktonic and biofilm states. The MIC90 for vancomycin-susceptible Enterococcus faecalis was 0.125 and 4μg/mL for dalbavancin and daptomycin, respectively. For vancomycin-resistant Enterococcus faecium, the MIC90 was >16 and 2μg/mL for dalbavancin and daptomycin, respectively. Dalbavancin minimum biofilm inhibitory concentrations (MBICs) for vancomycin-susceptible and -resistant isolates were ≤0.25 and >16μg/mL, respectively. The daptomycin MBIC90 for all isolates was 4μg/mL. For E. faecalis and E. faecium, dalbavancin minimum biofilm bactericidal concentrations (MBBCs) for vancomycin-susceptible and -resistant isolates were ≤4 and >16μg/mL, respectively, whereas vancomycin MBBCs were >128μg/mL for all isolates, and daptomycin MBBC90 values for both species were 128μg/mL. In summary, dalbavancin exhibited in vitro activity against all tested isolates of vancomycin-susceptible, but not against vancomycin-resistant enterococci; activity was observed in both the planktonic and biofilm states.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Dalbavancin, ≥90% (HPLC)